Belumosudil Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg
Reference Brands: Rezurock (USA)
Category:
Immune Disorder
Belumosudil is available in Tablets
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Belumosudil is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Belumosudil can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Belumosudil, marketed under the brand name Rezurock, is an oral targeted therapy used for the treatment of chronic graft-versus-host disease (cGVHD), a serious immune-mediated complication that can occur following allogeneic stem cell transplantation. It belongs to the class of serine/threonine kinase inhibitors and is specifically designed to inhibit Rho-associated coiled-coil kinase 2 (ROCK2).
ROCK2 plays a central role in regulating immune cell signaling pathways involved in inflammation and fibrosis. By selectively inhibiting ROCK2, belumosudil helps rebalance pro- and anti-inflammatory immune responses, thereby reducing chronic immune activation and tissue damage associated with cGVHD. This targeted mechanism allows for immune modulation without broad immunosuppression.
Preclinical and cellular studies have shown that belumosudil also influences several key biological pathways, including oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling. These additional effects may contribute to its therapeutic benefits in controlling immune dysregulation and fibrotic processes.
Administered orally, Rezurock provides a convenient treatment option for patients with limited alternatives after failure of prior systemic therapies. Its targeted approach represents an important advancement in the management of chronic graft-versus-host disease, offering improved disease control and quality of life for affected patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing